Join to View Full Profile
Massachusetts General Hospital55 Fruit StreetBoston, MA 02114
Phone+1 617-724-4000
Dr. Soumerai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jacob Soumerai is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from Tufts University School of Medicine and has been in practice at the MGH Cancer Center since 2017. He specializes in hematologic oncology and is experienced in chronic lymphoid leukemia and lymphoma.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2011 - 2014
Tufts University School of MedicineClass of 2011
Certifications & Licensure
MA State Medical License 2013 - 2026
NH State Medical License 2024 - 2026
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma Start of enrollment: 2019 Sep 01
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL Start of enrollment: 2020 Oct 19
- Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL Start of enrollment: 2020 Dec 15
- Join now to see all
Publications & Presentations
PubMed
- Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study.Tae Min Kim, Nehal J Lakhani, Jacob Soumerai, Manali Kamdar, Justin F Gainor
Haematologica. 2025-04-10 - 5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Ant...Hazim S Ababneh, Andrea K Ng, Joshua Wan, Tyler Walburn, Lin Zhu
International Journal of Radiation Oncology, Biology, Physics. 2025-04-03 - Characteristics and Outcomes of Patients with Double Refractory and Double Exposed Chronic Lymphocytic Leukemia.James T Yoon, Yinglu Zhou, Mariia Mikhaleva, Daniel Sungchul Choi, Stacey M Fernandes
Blood Advances. 2025-04-03
Abstracts/Posters
- A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...Jacob D. Soumerai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Time to Second Treatment As a Proxy for Overall Survival in CLL/SLL: Identifying Risk Factors to Help Guide Treatment SelectionJacob D. Soumerai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisoc...Jacob D. Soumerai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
IgG Testing, Immunoglobulin Replacement Therapy Improve Infection Outcomes in CLL, NHLAugust 16th, 2024- ASH 2022: MCL Trials Break New Ground, May Change PracticeJanuary 30th, 2023
- ‘Highly Encouraging’ MRD Results for Zanubrutinib Add-on in CLLJanuary 12th, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
